Logo image of UPC

UNIVERSE PHARMACEUTICALS INC (UPC) Stock Fundamental Analysis

NASDAQ:UPC - Nasdaq - KYG9442G1385 - Common Stock - Currency: USD

5.58  -0.45 (-7.46%)

After market: 5.41 -0.17 (-3.05%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to UPC. UPC was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of UPC have multiple concerns. UPC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

UPC had negative earnings in the past year.
In the past year UPC has reported a negative cash flow from operations.
In multiple years UPC reported negative net income over the last 5 years.
In multiple years UPC reported negative operating cash flow during the last 5 years.
UPC Yearly Net Income VS EBIT VS OCF VS FCFUPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

1.2 Ratios

UPC has a Return On Assets (-37.53%) which is in line with its industry peers.
With a Return On Equity value of -69.36%, UPC perfoms like the industry average, outperforming 48.99% of the companies in the same industry.
Industry RankSector Rank
ROA -37.53%
ROE -69.36%
ROIC N/A
ROA(3y)-3.37%
ROA(5y)11.69%
ROE(3y)-5.07%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
UPC Yearly ROA, ROE, ROICUPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 20 40 60

1.3 Margins

UPC has a Gross Margin (28.27%) which is in line with its industry peers.
In the last couple of years the Gross Margin of UPC has declined.
UPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.39%
GM growth 5Y-7.46%
UPC Yearly Profit, Operating, Gross MarginsUPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

3

2. Health

2.1 Basic Checks

UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
UPC has less shares outstanding than it did 1 year ago.
UPC has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, UPC has an improved debt to assets ratio.
UPC Yearly Shares OutstandingUPC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50K 100K 150K 200K
UPC Yearly Total Debt VS Total AssetsUPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.57, we must say that UPC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of UPC (0.57) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.08 indicates that UPC is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, UPC is in line with its industry, outperforming 53.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 0.57
ROIC/WACCN/A
WACC6.33%
UPC Yearly LT Debt VS Equity VS FCFUPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.63 indicates that UPC should not have too much problems paying its short term obligations.
UPC has a Current ratio of 1.63. This is in the lower half of the industry: UPC underperforms 68.18% of its industry peers.
A Quick Ratio of 1.46 indicates that UPC should not have too much problems paying its short term obligations.
The Quick ratio of UPC (1.46) is worse than 62.12% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.46
UPC Yearly Current Assets VS Current LiabilitesUPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

UPC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.04%.
Looking at the last year, UPC shows a very negative growth in Revenue. The Revenue has decreased by -22.32% in the last year.
The Revenue has been growing slightly by 2.53% on average over the past years.
EPS 1Y (TTM)-76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72693.73%
Revenue 1Y (TTM)-22.32%
Revenue growth 3Y1.72%
Revenue growth 5Y2.53%
Sales Q2Q%-30.23%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UPC Yearly Revenue VS EstimatesUPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UPC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UPC Price Earnings VS Forward Price EarningsUPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPC Per share dataUPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1K -2K -3K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

UPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIVERSE PHARMACEUTICALS INC

NASDAQ:UPC (5/21/2025, 8:00:01 PM)

After market: 5.41 -0.17 (-3.05%)

5.58

-0.45 (-7.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2022-02-11/dmh
Earnings (Next)N/A N/A
Inst Owners3.7%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.12M
Analysts0
Price TargetN/A
Short Float %14.67%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB 0.12
EV/EBITDA N/A
EPS(TTM)-3056.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.04
FCFYN/A
OCF(TTM)-10.91
OCFYN/A
SpS47.73
BVpS47.76
TBVpS47.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.53%
ROE -69.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.27%
FCFM N/A
ROA(3y)-3.37%
ROA(5y)11.69%
ROE(3y)-5.07%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.39%
GM growth 5Y-7.46%
F-Score2
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.74%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.46
Altman-Z 0.57
F-Score2
WACC6.33%
ROIC/WACCN/A
Cap/Depr(3y)41.15%
Cap/Depr(5y)31.41%
Cap/Sales(3y)0.43%
Cap/Sales(5y)0.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72693.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-22.32%
Revenue growth 3Y1.72%
Revenue growth 5Y2.53%
Sales Q2Q%-30.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-342.17%
FCF growth 3Y-43.83%
FCF growth 5Y-24.24%
OCF growth 1Y-303.48%
OCF growth 3Y-43.22%
OCF growth 5Y-24.14%